RT Journal Article
T1 A new fructose-free, resistant-starch type IV-enriched enteral formula improves glycaemic control and cardiovascular risk biomarkers when administered for six weeks to elderly diabetic patients.
A1 Mesa-Garcia, Maria Dolores
A1 Garcia-Rodriguez, Cruz Erika
A1 Rico, Maria de la Cruz
A1 Aguilera, Concepcion Maria
A1 Perez-Rodriguez, Milagros
A1 Perez-de-la-Cruz, Antonio Jesus
A1 Gil, Angel
K1 Diabetes mellitus type 2
K1 Cardiovascular risk
K1 Enteral nutrition
K1 Glycaemic control
K1 Glycated haemoglobin
K1 Resistant-starch type IV
AB Reducing the dietary glycaemic response has been proposed as a way to reduce the risk of diabetes complications. The aim of the present study was to evaluate the glycaemic control and cardiovascular risk biomarkers in fragile, elderly type 2 diabetes patients after the intake of a new fructose-free diabetes-specific formula enriched with resistant-starch type IV and high in monounsaturated fatty acids. Forty-one type 2 diabetes patients aged 78.9 ± 2.8 years were fed exclusively with an enteral diabetes-specific formula for 6 weeks. Data were collected at baseline and after 6 weeks of feeding. Carbohydrate and lipid metabolism and inflammatory and cardiovascular risk biomarkers were measured to evaluated the course of diabetes complications. Blood glycated haemoglobin significantly decreased after the intervention (6.1 ± 0.1 vs. 5.8 ± 0.1 %; p The new product improves glycaemic control and cardiovascular risk without altering lipid metabolism, which is useful for the prevention of diabetic complications. Longer intervention studies are needed in order to validate these results in a larger population.
PB Aula Medica Ediciones
YR 2017
FD 2017-02-01
LK http://hdl.handle.net/10668/10915
UL http://hdl.handle.net/10668/10915
LA en
NO Mesa García MD, García-Rodríguez CE, Rico MC, Aguilera CM, Pérez-Rodríguez M, Pérez-de-la-Cruz AJ,  et al. A new fructose-free, resistant-starch type IV-enriched enteral formula improves glycaemic control and cardiovascular risk biomarkers when administered for six weeks to elderly diabetic patients. Nutr Hosp. 2017 Feb 1;34(1):73-80.
DS RISalud
RD Apr 18, 2025